you Thanks, interest in Dave. your Halyard for thank and everyone Health. Good morning
of execution and our closed new as of strong IT we we to the delivered another earnings, installation year, quarter start system. our cost initiating the by S&IP and begin Let momentum, saying a that off the with reshaping divestiture, top-line me continue structure began our sales solid to are
in our on outlined goals are conference XXXX last call. quarter's to on continue deliver four excellent to that an position We for I
for factors execution. growth for interventional continue as more organic continued top-line commercial with demand including a pain. well-positioned continued growth momentum seen the we've focused Multiple quarter, company drove X% and sales our First, to enhance COOLIEF double-digit we're and to
our severe with portfolio flu sales. oral and surgical health digestive growth season, year's more In the along a impacted care for respiratory drove Solid continued two to CORPAK cold quarter. contract, And pain, pump health. ON-Q demand for drive factors volume last in
fill bupivacaine which on educating through shortage First, their findings the key expected accounts a from the increased outlook remains to these industry-wide surgical continue as our audit. to second, FDA with the we to continue deepen convert second sales headwinds, to pumps is pump positive fellow's our new focus quarter; due inability Despite penetration surgeons. and
a to the opioid post-operative the for Our outreach threatening of for in opioid perspective, to solution days extended we of of pain In days. use. use. pain important earnings that of role non-opioid well-positioned our ON-Q adjusted $X.XX physicians therapy five can relief per addiction seek and as is Halyard delivered opioids. diluted ON-Q non-opioid opioid an resonating efficacy quarter, From control life a is effective the play ahead expectations. share reducing offers and benefits alternatives clinically within superior management, pain begin highlights as three is just first and an earnings
and For earnings discontinued diluted between year, share of earn per the expect adjusted we $X.XX and $X.XX to operations. continuing from
growth our company become high-growth medical capacity million a $XXX focused attractive complete, the strategy. roughly device markets execute in end dual-track pure-play of to divestiture we With have now acquisition high-margin, with
cost as more adjustable on structure. and And we're right-sizing evaluating our efficiencies We expand markets. driving are wider a M&A agile finally, us smaller a and through focused actively technologies, points, increase lens. Exploring areas that corporate opportunities help our leverage our call company,
IT internal generate XXXX. system help new support During completed our $XX million of will more cost to areas, This the $XX million in M&A of activity. speed structure quarter, we which growth, of when efficient began cost will reduce our installation integration savings and other the in
working ensure we corporate cost, the capitalize necessary are reduce ahead. also to the well-positioned efficiencies, are drive are strategic investments we we making opportunities on and While to to
strategic me made four investments growth that Let highlight examples during quarter of the we our strategy. support
from launched device XX% our First, XX our The consistently are projects. French compared most products. investment year our significant which increased digestive GJ to the of our shifting In we competitive the position transformative the portfolio. we health investment strengthened R&D four R&D medical sustaining quarter, first prior was MIC-KEY* Tube to and
than in investment expected continues is year. and our XX% clinical Second, more studies this to grow
the initiated to study the other we including therapies randomly Acid. of favorable is new as controlled quarter, patient COOLIEF to Enrolment today used show in differentiation a planned. XXX widely this During Hyaluronic study progressing
pain we AdvaMed, government management efforts, Additionally, robust its our and therapies. a Through of current my improve I team reimbursement alongside and effort through to are impact engaging legislation relations working medical devices in are way to non-opioid the other aiming Congress. help
full Vice with performance. Finally, President Vice we will Asia-Pacific new this leadership about I as see we solid Day International the as top-line will to roles forward we details Arjun domestic and behind and our growth. international to achieve success to strategy of region. in opportunity for Arjun our served are to Manager trailed and more leadership, call recently XXst accelerate New lead Asia. our served over York. who that, we regions strengthen of With Southeast well-positioned with and our record believe Prior drive the Steve. Manager on an driving at commercial report We President and Halyard's us, quarter opportunities me. first turn a team, General our With growth. XXXX. to acceleration revenue appointed and track experience momentum, continue appointment, create goals. see streamlined He brings sharing Growth Covidien focus Sarker, To an deep business solid international Arjun to effort, their of XXXX efficiencies, and our Vice in and President also our has business, look Analyst one June in General With to but our his focus held of our leadership can as we we of increased Senior will